Dusigitumab

DB12363InvestigationalProtein Based Therapies

Dusigitumab has been used in trials studying the treatment of Cancer, Advanced Solid Malignancies, Unresectable or Metastatic Hepatocellular Carcinoma (HCC), and Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer.

Mechanism: Pharmacologically active on Insulin-like growth factor 1 and Insulin-like growth factor 2
Curator reviewed
Code names: MEDI-573

Resolves to

Compound

UNII0Z70DT5PRXCAS1204390-13-5

Targets

P05019IGF1P01344IGF2

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

381Drug interactionsStructured to mechanism, not free text

4Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Dusigitumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account